Bulevirtide for hepatitis D: bile acids and gut bacteria
Part of Cancer, Digestive system, Immune system & allergy, Infections clinical trials.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis D with stable liver disease (Child-Pugh class A)
- You have had a positive HDV RNA test in the last 6 months
- You are already taking medication for hepatitis B
- You are starting Bulevirtide within 30 days of joining the study
- You are 18 or older and have not taken antibiotics, probiotics, or prebiotics in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking for adults in Turkey who have had a hepatitis B infection (HBsAg positive) for at least 6 months. The goal is to see if they also have a hepatitis D virus (HDV) infection. This may help doctors better understand and treat these infections.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at how well the drug bulevirtide (BLV) works over a long period for people with hepatitis D (HDV) and liver scarring that is still under control (compensated cirrhosis). It may help you if you have been taking BLV alone and want to see how your liver and health have been doing.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.